Skip to main navigation Skip to search Skip to main content

Effect of dysmagnesaemia and its correction on mortality of non-critically ill hospitalized medical patients

  • Donna Gal
  • , Eugene Feigin
  • , Daniel Shepshelovich
  • , Moshe Giladi
  • Tel Aviv Sourasky Medical Center
  • Columbia University

Research output: Contribution to journalArticlepeer-review

Abstract

Magnesium is an essential electrolyte, regulating enzymatic function and membrane excitability. While dysmagnesaemia is common among hospitalized patients, its prognostic role and the potential clinical benefit of its correction remain debated. Methods: All adult patients admitted to internal medicine wards at the Tel-Aviv Sourasky Medical Center between June 1st, 2007, and July 31st, 2022, for whom magnesium levels were measured, were included. Data from 85,466 patients were obtained. Patients were divided into four subgroups according to magnesium level at admission: severe hypomagnesaemia (serum magnesium ≤1.2mg/dL), mild hypomagnesaemia (magnesium >1.2mg/dL≤1.8mg/dL), eumagnesaemia (magnesium >1.8/≤2.55mg/dL), and hypermagnesaemia (magnesium >2.55). The primary outcome was 30-day mortality risk. Results: Hypomagnesaemia was associated with the use of thiazides and proton pump inhibitors (p<0.001), while severe hypermagnesaemia was associated with reduced renal function (p<0.001). After adjusting for age, gender, the Charlson comorbidity index, creatinine, potassium, and calcium corrected for albumin, mild hypomagnesaemia was associated with lower 30-day mortality (HR: 0.87, 95% CI: 0.82-0.93, p<0.001), hypermagnesaemia was associated with higher 30-day mortality (HR: 2.86, 95% CI: 2.57-3.17, p<0.001), and severe hypomagnesaemia was not associated with survival change (HR: 0.82, 95% CI: 0.62-1.09, p=0.177). Hypermagnesaemia normalization (HR: 0.77, 95% CI: 0.63-0.93, p<0.001) and administration of magnesium supplements for mild (adjusted HR: 0.53, 95% CI: 0.36-0.79, p=0.002) or severe (HR: 0.34, 95% CI: 0.28-0.41, p<0.001) hypomagnesaemia were associated with reduced mortality. Conclusion: In hospitalized, non-critically ill medical patients, hypermagnesaemia confers a substantial 30-day mortality risk, which may be mitigated by its correction. Although hypomagnesaemia is not associated with worse outcome, its correction by supplementation may be of clinical benefit.

Original languageEnglish
Pages (from-to)17-25
Number of pages9
JournalMagnesium Research
Volume38
Issue number1
DOIs
StatePublished - 1 Jan 2025
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2025 JLE.

Keywords

  • PPI
  • diuretics
  • hypermagnesaemia
  • hypomagnesaemia
  • magnesium
  • mortality

Fingerprint

Dive into the research topics of 'Effect of dysmagnesaemia and its correction on mortality of non-critically ill hospitalized medical patients'. Together they form a unique fingerprint.

Cite this